Allen & Overy has advised Exscientia on its USD674 million AI drug discovery collaboration with Merck KGaA. Collaboration is set to harness Exscientia’s precision design capabilities...
You must be a Standard 1 Year member to access this content.
Allen & Overy has advised Exscientia on the matter. Sanofi and Exscientia announced a ground breaking research collaboration and licence agreement to develop up to 15...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
You must be a Standard 1 Year member to access this content.
Allen & Overy has advised Exscientia on the matter. The collaboration will leverage Exscientia’s AI-driven drug discovery platform to accelerate the discovery of multiple small molecule...
You must be a Standard 1 Year member to access this content.
Allen & Overy has advised Exscientia on the deal. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Exscientia on the deal. Exscientia, a clinical-stage pharmatech company, announced its $225 million Series D funding round led by SoftBank Vision Fund 2, which...
You must be a Standard 1 Year member to access this content.
